• Pharmacology lead for a bispecific HETmAb approach in SLE – driving Lead Discovery activities for critical path assays, including running/ developing primary cell screens and developing secondary assays using PBMCs to demonstrate the advantage of the bispecific.• Biology lead for targeted macrophage inhibitors – defining and driving the biology strategy for a targeted macrophage inhibitor in RA, in addition to designing and running phenotypic assays (e.g., cytokine stimulated monocytes and cellular acid retention studies) alongside CETSA to demonstrate target engagement and setting up work packages at CRO’s.• Department lead for UK Industrial Placement Students- working across all resource and operational leads to determine scope, consulting with recruitment, leading interview process and training new interviewers, point of contact for onboarding and responsible for pastoral aspects during placement year.

Exploring Epigenetic Targets in Immuno-inflammation & Cancer• Translational lead for targetted (ESM) BET inhibitors, supporting FTIH studies. Key roles were:1. Determining pharmacology of ESM-BET inhibitors: identified and profiled molecules from Lead Optimisation through to post-candidate selection. 2. Establishing clinical readouts for pillars 1-3 (intracellular PK monocyte assay, novel gene panel ID and validation, Truculture tube assay validated and transferred to Phase I clinical unit).3. Experimental Medicine study establishing 3 immune challenges- blisters, LPS and GM-CSF to identify safe and optimal conditions to test the pharmacology of new ESM-BET molecules. Part of dose escalation committee, review of all biomarker data, clinical protocol and other study documentation. • Lead biologist in team developing BET inhibitors for use in oncology; designed and conducted key experiments to support progression into clinical development. Established translational biomarkers, including gene expression panels and LPS Truculture assays to measure target engagement, establishing time and event selection for biomarkers as well as implementation in the clinic and subsequent data interpretation.• Co-ordinated Systemic Sclerosis patient sample study with the Royal Free Hospital / UCL to support indication expansion for BET inhibitors, including gene expression and protein expression endpoints.• Central role in the generation of data packages to support the progression of multiple epigenetic targets e.g., BET family BRD4, BD1 and BD2 including establishing proliferation assays in cancer cell lines, Western blotting to confirm target expression/ modification, LPS and Resiquimod stimulated human and mouse whole blood.• Investigated role of LPA/ LPA receptor HUVEC permeability including the use of CellKey Label Free Technology.• Key role in safety management – responsible for safety within department and representative at site Biology meetings.

April 2020 - July 2020: CNCTC (Cambridge National COVID Testing Centre), Team Leader• GSK voluntary secondment to CNCTC throughout Phase I & transition to Phase II. The CNCTC was one of five Lighthouse labs and rapidly set up in April by GSK, AstraZeneca and University of Cambridge as part of the UK Government’s ‘Test and Trace’ program.• Part of multi-disciplinary team to establish infrastructure and protocols to deliver >10K samples/day, working across the 3 organisations to set up a robust, sensitive, and high throughput system.• Team Leader responsible for PCR function leading six scientists from across the organisations. Personnel, safety, training, delivery and sustainability were constantly evolving but of paramount importance. Role involved close collaboration across the other functions, particularly the preceding RNA team and subsequent off-site Data Analysis team, the Shift Directors and the incoming shift PCR team.

• Key role in passive vaccination approach to Alzheimer’s disease, including establishing a variety of novel ELISAs and critical path screens to differentiate molecules and progress to candidate selection, including epitope mapping, antibody/ target complex measurements and analysis of in vivo samples to model candidate efficacy. • Critical role in analysis of post candidate “translational” novel model of A deposition in non-human primates.• Established immunoprecipitation techniques for SELDI/MALDI analysis of A species in cell supernatants for Gamma secretase modulator approaches.• ELISA/Western techniques developed to monitor A expression in the TAS10 APP (amyloid precursor protein) transgenic mouse.• Prepared primary hippocampal and cortical neuronal cultures from transgenic mice.• Utilised recombinant and rat primary microglia to study the actions of LPS and A on the production of inflammatory mediators to investigate compounds directed against target proteins, including COX-2, iNOS, PPAR-, P38/ JNK & ERK MAPK's, FPRL-1, MSK-1 and MK2. • Western blotting/ immunoprecipitation techniques used to interrogate upregulation of a number of putative target inflammatory proteins and help understand interactions between signal transduction pathways.

Analysis of the mode of action of novel small molecule c-erbB2 tyrosine kinase inhibitors:• Generation of a range of stable human recombinant cell lines expressing a range of tyrosine kinases, including c-erbB2, c-erbB4 and v-src, and subsequent analysis of pathways involved in target protein cell signalling.